Belzutifan Plus Pembro Approved for Adjuvant RCC M. Alexander Otto, PA, MMSc June 12, 2026

https://www.medscape.com/viewarticle/belzutifan-plus-pembro-approved-adjuvant-rcc-2026a1000jxb The FDA has approved belzutifan (Welireg, Merck) in combination with pembrolizumab (Keytruda, Merck) or the subcutaneous formulation of pembrolizumab (Keytruda Qlex, Merck) for the adjuvant treatment of adults with clear cell renal cell carcinoma.